Catalent dans l'actualité
Partenaire de fabrication pour le développement de médicaments
Tamtam a trouvé 20 articles récents sur Catalent.
- Catalent launches ten-month gene-to-drug substance programme for complex biologics
- Catalent, Inc. Launches Accelerated Gene-To-Drug Substance Program For Complex Biologics In The U.S
- Catalent Launches Accelerated Gene-to-Drug Substance Program for Complex Molecules in the U.S.
- Catalent Launches Accelerated Gene-to-Drug Substance Program in US for Complex Biologics
- ALK-Abelló (CPSE:ALK B) Expands Catalent Deal, Is The 32% Undervaluation Case Convincing?
- ALK expands Catalent partnership: what it means for Catalent stock
- ALK expands strategic tablet supply partnership with Catalent
- ALK expands Catalent partnership – guidance is maintained
- ALK Expands Tablet Supply Partnership With Catalent
- ALK, Catalent Expand Long-Term Contract Manufacturing Collaboration
- ALK expands strategic tablet supply partnership with Catalent
- Catalent stock reports USD 4.7 billion refinancing
- Catalent stock holds near its yearly low as earnings lag
- Catalent stock gains after FDA clears key manufacturing site
- Catalent stock holds steady as investors await fresh earnings and guidance
- Catalent lands $4.1B debt deal to expand biologics and oral drug capacity
- Catalent uses AI on Azure to strengthen quality management system processes
- Catalent Completes $4.1 Billion Debt Refinancing To Cut Annual Interest Expense By $100 Million
- Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
- Catalent Completes Successful Debt Refinancing
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Catalent ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires